Alzinova initiates Phase 2 operational start-up for ALZ-101
Alzinova AB said it, together with contract research organization Worldwide Clinical Trials, has initiated the operational start-up phase of the Phase 2 study of vaccine candidate ALZ-101 for treatment of Alzheimer’s disease.